Does cilostazol cause coronary vasodilation and improve myocardial perfusion in patients with coronary artery disease?

Cilostazol Does Cause Coronary Vasodilation in Humans

Yes, cilostazol produces mild-to-moderate coronary vasodilation and improves epicardial coronary artery diameter, though this effect is substantially weaker than nitroglycerin and does not translate into proven reduction of cardiovascular ischemic events (MI, stroke, or cardiovascular death) in patients with coronary artery disease. 1, 2

Direct Evidence of Coronary Vasodilation

• A single 200 mg oral dose of cilostazol significantly increased luminal cross-sectional areas of major epicardial coronary arteries by 14–42% at 150 minutes post-administration in humans undergoing quantitative coronary angiography. 2

  • Right coronary artery: 25% increase proximally and 42% distally
  • Left anterior descending: 24% proximally and 28% distally
  • Left circumflex: 14% proximally and 24% distally 2

• This coronary vasodilating action was approximately 27–54% of the magnitude achieved with nitroglycerin, indicating a mild but measurable effect. 2

• The vasodilation occurred with minimal hemodynamic perturbation—only small decreases in systolic pulmonary pressure and stroke work index were observed, without clinically significant hypotension. 1, 2

Mechanism of Coronary Vasodilation

• Cilostazol is a phosphodiesterase-III inhibitor that raises intracellular cyclic AMP in vascular smooth muscle, producing direct arterial vasodilation. 3

• The vasodilatory effect is more pronounced in femoral arteries than in vertebral, carotid, or mesenteric vessels, but coronary arteries do respond with measurable dilation. 3

• Beyond vasodilation, cilostazol exerts antiproliferative effects on vascular smooth muscle and suppresses VCAM-1 expression, which may contribute to anti-restenotic properties after coronary interventions. 3, 4

Critical Limitation: No Cardiovascular Protection

Despite causing coronary vasodilation, cilostazol does NOT reduce cardiovascular ischemic events (MI, stroke, or cardiovascular death) in patients with established coronary artery disease. 1

• The ACC explicitly states that cilostazol lacks cardiovascular protective effects and can even exacerbate angina pectoris or precipitate myocardial infarction in patients with ischemic heart disease. 1

• Long-term safety data (>2,000 patients, up to 6 months) showed cardiovascular death rates of 0.6% with cilostazol versus 0.5% with placebo—no mortality benefit despite symptomatic improvement in claudication. 5

Absolute Contraindication in Heart Failure

• Cilostazol is absolutely contraindicated in any patient with heart failure of any severity, regardless of ejection fraction or NYHA class, due to FDA black-box warning based on increased mortality with phosphodiesterase-III inhibitors in this population. 1, 3, 5

• Post-MI patients frequently develop heart failure or subclinical left ventricular dysfunction, making cilostazol particularly hazardous in this population. 1

Clinical Context: When Coronary Vasodilation Matters

• The coronary vasodilating property may contribute to cilostazol's utility as adjunctive antiplatelet therapy after percutaneous coronary intervention (PCI), where it has been shown to reduce restenosis rates without increasing bleeding when added to dual antiplatelet therapy. 4, 6

• Small studies suggest cilostazol may prevent thrombosis and restenosis following PCI, though these remain off-label uses. 7

• The drug's "pleiotropic" effects—antiplatelet, vasodilating, antiproliferative, and lipid-modifying (10% HDL increase, 15% triglyceride reduction)—make it mechanistically attractive, but clinical outcomes data for coronary protection remain absent. 3, 4, 7

Practical Implications

• If considering cilostazol in a patient with known coronary disease, verify absence of heart failure symptoms, stable coronary status without ongoing ischemia, and understand that the coronary vasodilation will not prevent future MI or cardiovascular death. 1, 5

• For post-MI patients with peripheral artery disease, aspirin (75–325 mg daily) or clopidogrel (75 mg daily) remains the recommended antiplatelet strategy to reduce MI, stroke, and vascular death—not cilostazol. 1

• The 100 mg twice-daily dose (taken ≥30 minutes before or ≥2 hours after meals) is required for maximal effect; the 50 mg dose is significantly less effective. 5